updated 6/23/2011 7:16:01 AM ET 2011-06-23T11:16:01

DALLAS, June 23, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring Achillion Pharmaceuticals Inc. (Nasdaq:ACHN). The report details the company's recent developments and news, outlines its financial position, and recaps comparative and analyst consensus.

The full report is available at: www.microstockprofit.com/lp/ACHN

Achillion Pharmaceuticals Inc. (ACHN) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, it is currently concentrating on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2009, ACHN focused on developing three Hepatitis C virus (HCV) drug candidates.

This newsletter has been helping traders make great investment decisions on ACHN; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of ACHN spiked almost 21% in yesterday's trading after the biopharmaceutical company announced the pricing of the public offering of its common stock. The New Haven, Connecticut-based company said it plans to sell 9.6 million shares at $5.90 a share, down from the previous session's closing price of $6.01."

"Also yesterday, the Company announced that it has initiated patient dosing in segment 2 of its phase II clinical trial of ACH-1625 for the treatment of hepatitis C virus (HCV) for genotype 1 treatment naïve HCV-infected patients. ACH-1625, discovered and advanced by ACH, is a potent small molecule inhibitor of HCV protease, an enzyme necessary for viral replication."

To read the entire report visit: www.microstockprofit.com/lp/ACHN

See what investors are saying about ACHN at http://www.stockhideout.com

Get breaking news on ACHN at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Jay Geller

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com